TACR1 and cancer: In summary, the widespread presence of SP/NK1R in oral carcinomas strongly suggests their important role in cancer progression, and we also would like to highlight the need for clinical trials to check the potential use of NK1R antagonists, such Aprepitant, for the management of patients with oral cancer.